Endpoints News 1. Mai 2026 FDA approval for Alzheimer's agitation drug; Esperion goes private in $1.1B deal
Endpoints News 1. Mai 2026 Summit slips on ivonescimab's apparent interim miss in sign of investor frustration
Endpoints News 1. Mai 2026 Boehringer appoints pharma veteran for corporate affairs post; BlueRock CSO heads for the exit
Endpoints News 30. Apr. 2026 FDA's oncology advisors vote against 'new paradigm' in AstraZeneca trial
Endpoints News 30. Apr. 2026 Krazati fails confirmatory trial in colorectal cancer, putting approval at risk
Endpoints News 30. Apr. 2026 House panel calls to ban China trial data from FDA drug trial applications
Endpoints News 30. Apr. 2026 Court dismisses part of Lilly lawsuit against Empower, some claims can proceed
Endpoints News 30. Apr. 2026 Supreme Court questions how far generics makers can go with 'skinny label' drugs
Endpoints News 30. Apr. 2026 Lack of specifics on obesity pill sales hover over Lilly’s first quarter
Endpoints News 30. Apr. 2026 The R&D 15: How pharma's top companies spent, won and lost on drug research